Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAURA2 adjuvant osimertinib in resected EGFR-mutated stage IA2-IA3 non-small cell lung cancer
2023-509943-28-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Adjuvant osimertinib with Placebo (2 arms). Primary endpoint: Disease-free survival in the high-risk stratum by investigator assessment. Planned start May 2022; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509943-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509943-28-00.